Latest Healthcare It News

Prescient Therapeutics has achieved a key regulatory milestone with the European Medicines Agency granting Orphan Drug Designation for its PTX-100 therapy targeting Cutaneous T-cell Lymphomas, enhancing its commercial and clinical prospects in Europe.

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Decidr AI Industries has announced a strategic acquisition of Delaware-based Sugarwork Inc., marking its official entry into the US market and enhancing its Agentic AI platform with advanced knowledge transfer capabilities.

Cyclopharm Limited reaffirms its ambitious target of 250–300 US Technegas installations by late 2026, driven by FDA approval, CMS reimbursement, and a growing pipeline of healthcare sites. The company reports record half-year revenue growth, signaling strong momentum in the expanding lung imaging market.

EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its Dyspro and Libbo therapies.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.

Visionflex Group Limited has successfully passed all resolutions at its 2025 Annual General Meeting, reinforcing its governance framework and capital strategy.

Regis Healthcare reported robust FY25 financial results and outlined ambitious expansion plans targeting 10,000 beds by FY28, while urging urgent government reforms to address the sector’s undersupply of quality aged care.

Tryptamine Therapeutics has enrolled its second patient in a pioneering clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with first dosing scheduled for December and results expected early next year.

Radiopharm Theranostics has secured ethics approval to begin a Phase 1 clinical trial of RAD 402, a pioneering radiotherapeutic targeting advanced prostate cancer using terbium-161. This marks a significant step in developing a potentially safer, more effective treatment option.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.